Issues Related to Clinical Trials of Oral and Biologic Disease-Modifying Agents for Sjogren's Syndrome

被引：5
作者：
Carsons, Steven E. [1 ,2 ]
机构：
[1] Winthrop Univ Hosp, Div Rheumatol Allergy & Immunol, Mineola, NY 11501 USA
[2] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2008年 / 34卷 / 04期
关键词：
Sjogren's; Clinical trials; DMARD; Biologics; Outcome; Study design;
D O I：
10.1016/j.rdc.2008.08.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Published studies and trials of oral and biologic disease-modifying antirheumatic drugs for the treatment of Sjogren's syndrome have shown disappointing results. Improvements in trial design, including development of consortia for the conduct of national and international multicenter studies and use of standardized classification and outcome measures coupled with the emergence of newer biologic, immunomodulatory, and small molecule agents, hopefully will result in the addition of disease-modifying agents to the armamentarium.
引用
收藏
页码：1011 / +
页数：14
相关论文
共 43 条
[1]  
Alsalameh S, 1999, SCAND J IMMUNOL, V49, P278
[2]   Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sjogren's syndrome patients [J].
Aragona, P ;
Bucolo, C ;
Spinella, R ;
Giuffrida, S ;
Ferreri, G .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (12) :4474-4479
[3]   D-penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjogren's syndrome [J].
Asahina, M ;
Kuwabara, S ;
Asahina, M ;
Nakajima, M ;
Hattori, T .
NEUROLOGY, 1998, 51 (05) :1451-1453
[4]   Sjogrens Systemic Clinical Activity Index (SCAI)a systemic disease activity measure for use in clinical trials in primary Sjgrens syndrome [J].
Bowman, S. J. ;
Sutcliffe, N. ;
Isenberg, D. A. ;
Goldblatt, F. ;
Adler, M. ;
Price, E. ;
Canavan, A. ;
Hamburger, J. ;
Richards, A. ;
Rauz, S. ;
Regan, M. ;
Gadsby, K. ;
Rigby, S. ;
Jones, A. ;
Mathew, R. ;
Mulherin, D. ;
Stevenson, A. ;
Nightingale, P. .
RHEUMATOLOGY, 2007, 46 (12) :1845-1851
[5]  
CARSONS S, 2005, KELLEYS TXB RHEUMATO, V2, P1105
[6]   Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results [J].
Cummins, MJ ;
Papas, A ;
Kammer, GM ;
Fox, PC .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (04) :585-593
[7]  
DANIELS T, 1987, SJOGRENS SYNDROME CL
[8]  
DROSOS AA, 1988, CLIN EXP RHEUMATOL, V6, P53
[9]   CYCLOSPORINE-A (CYA) IN PRIMARY SJOGRENS-SYNDROME - A DOUBLE-BLIND-STUDY [J].
DROSOS, AA ;
SKOPOULI, FN ;
COSTOPOULOS, JS ;
PAPADIMITRIOU, CS ;
MOUTSOPOULOS, HM .
ANNALS OF THE RHEUMATIC DISEASES, 1986, 45 (09) :732-735
[10]  
DROSOS AA, 1986, SCAND J RHEUMATOL, P246
12345